Core Viewpoint - Huazhang Biopharma-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, raising approximately HKD 600 million through the issuance of 17.6488 million shares, but the stock has seen a decline of 11.52% to HKD 33.8 at the time of reporting [1] Company Overview - Established in 2012, Huazhang Biopharma is a biopharmaceutical company based in China, focusing on the development of therapies, particularly protein drugs targeting medical needs and market opportunities [1] - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1] Product Pipeline - The two core products in the pipeline are Pro-101-1 for treating burns and Pro-101-2 for treating diabetic foot, both of which are rhPDGF-BB drugs [1] - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no PDGF drugs approved in the country [1] - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharma, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1]
华芢\生物-B首挂上市 早盘低开11.52% 公司为中国领先PDGF药物生物制药企业